Biomea Fusion, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BMEA Nasdaq 2836 biomeafusion.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biomea Fusion, Inc.

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights - Aug 5th, 2026 2:05 pm
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study - Jun 5th, 2026 5:32 pm
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity - Jun 3rd, 2026 6:00 am
Biomea Fusion to Participate at Upcoming Investor Conferences - May 12th, 2026 2:05 pm
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights - May 11th, 2026 2:54 pm
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions - May 5th, 2026 3:50 pm
Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026 - May 5th, 2026 2:20 pm
Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib - Apr 28th, 2026 2:31 pm
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment - Apr 27th, 2026 3:37 pm
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies - Mar 31st, 2026 5:00 am
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts - Mar 30th, 2026 3:03 pm
Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes - Mar 30th, 2026 12:24 pm
Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth? - Mar 27th, 2026 4:26 am
Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results - Mar 25th, 2026 1:32 pm
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights - Mar 24th, 2026 2:05 pm
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 - Mar 14th, 2026 2:30 am
Biomea Fusion Details Diabetes, Obesity Pipeline at Citizens Conference, Sees Cash Runway to Q1 2027 - Mar 13th, 2026 1:28 am
Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf. - Feb 26th, 2026 9:14 pm
Biomea Fusion, Inc.'s (NASDAQ:BMEA) largest shareholders are retail investors with 55% ownership, institutions own 38% - Jan 24th, 2026 6:09 am
Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price Target - Jan 19th, 2026 6:01 am